Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic.
Hannah R MathewMay Y ChoiMichael D ParkinsMarvin J FritzlerPublished in: BMC pulmonary medicine (2021)
Although individuals with CF are at risk of acute exacerbations often precipitated by respiratory tract viral infections, published evidence to date indicated that individuals with CF do not experience higher risks of contracting SARS-CoV-2 infection. However, there is evidence that some subsets within the CF population, including those post-transplantation, may experience a more severe clinical course. As SARS-CoV-2 variants are identified and the pandemic goes through additional waves of disease outbreaks, ongoing monitoring of the risk of COVID-19 in individuals with CF is required.
Keyphrases
- sars cov
- cystic fibrosis
- respiratory syndrome coronavirus
- pseudomonas aeruginosa
- systematic review
- respiratory tract
- lung function
- meta analyses
- liver failure
- drug induced
- stem cells
- randomized controlled trial
- chronic obstructive pulmonary disease
- cell therapy
- peripheral blood
- respiratory failure
- aortic dissection
- mesenchymal stem cells
- risk assessment
- air pollution
- gene expression